Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Cachexia, Sarcopenia and Muscle
Literature
1.
Russ DW, Grandy JS. Increased desmin expression in hindlimb muscles of aging rats. J Cachex Sarcopenia Muscle. 2011;2:175–80.CrossRef
2.
Pan Y, Jing R, Pitre A, Williams BJ, Skalli O. Intermediate filament protein synemin contributes to the migratory properties of astrocytoma cells by influencing the dynamics of the actin cytoskeleton. FASEB J. 2008;22:3196–206.PubMedCentralPubMedCrossRef
3.
Heo DH, Kim SH, Yang KM, et al. A histopathological diagnostic marker for human spinal astrocytoma: expression of glial fibrillary acidic protein-delta. J Neurooncol. 2012;108:45–52.PubMedCrossRef
4.
Pitre A, Davis N, Paul M, Orr AW, Skalli O. Synemin promotes AKT-dependent glioblastoma cell proliferation by antagonizing PP2A. Mol Biol Cell. 2012;23:1243–53.PubMedCentralPubMedCrossRef
5.
Sakamoto Y, Boeda B, Etienne-Manneville S. APC binds intermediate filaments and is required for their reorganization during cell migration. J Cell Biol. 2013;200:249–58.PubMedCentralPubMedCrossRef
6.
Engstrom PG, Tommei D, Stricker SH, Ender C, Pollard SM, Bertone P. Digital transcriptome profiling of normal and glioblastoma-derived neural stem cells identifies genes associated with patient survival. Genome Med. 2012;4:76.PubMedCentralPubMedCrossRef
7.
Murayama H, Sadakane K, Yamanoha B, Kogure S. Low-power 808-nm laser irradiation inhibits cell proliferation of a human-derived glioblastoma cell line in vitro. Lasers Med Sci. 2012;27:87–93.PubMedCrossRef
8.
Noetzel E, Rose M, Sevinc E, et al. Intermediate filament dynamics and breast cancer: aberrant promoter methylation of the Synemin gene is associated with early tumor relapse. Oncogene. 2010;29:4814–25.PubMedCrossRef
9.
Kanakkanthara A, Teesdale-Spittle PH, Miller JH. Cytoskeletal alterations that confer resistance to anti-tubulin chemotherapeutics. Anticancer Agents Med Chem. 2013;13:147–58.PubMedCrossRef
10.
11.
Liu YH, Cheng CC, Ho CC, et al. Effects of diode 808 nm GaAlAs low-power laser irradiation on inhibition of the proliferation of human hepatoma cells in vitro and their possible mechanism. Res Commun Mol Pathol Pharmacol. 2004;115–116:185–201.PubMed
12.
Ho CC, Ho HC, Liu YH, et al. Altered synemin could affect the organization of intermediate filament in human hepatocellular carcinoma. J Med. 2004;35:171–80.PubMed
Metadata
Title
Synemin: an evolving role in tumor growth and progression
Author
Shailendra Kapoor
Publication date
01-12-2014
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cachexia, Sarcopenia and Muscle / Issue 4/2014
Print ISSN: 2190-5991
Electronic ISSN: 2190-6009
DOI
https://doi.org/10.1007/s13539-013-0122-x

Other articles of this Issue 4/2014

Journal of Cachexia, Sarcopenia and Muscle 4/2014 Go to the issue

Review

Rehabilitation nutrition for sarcopenia with disability: a combination of both rehabilitation and nutrition care management

Original Article

Does IGFR1 inhibition result in increased muscle mass loss in patients undergoing treatment for pancreatic cancer?

Original Article

Modeling human cancer cachexia in colon 26 tumor-bearing adult mice

Review

Cachexia: a problem of energetic inefficiency

Original Article

Ventricular assist device implantation improves skeletal muscle function, oxidative capacity, and growth hormone/insulin-like growth factor-1 axis signaling in patients with advanced heart failure

Editorial

Prevalence, incidence and clinical impact of cachexia: facts and numbers—update 2014
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits